AOD 9604, MOTS-c, Tesamorelin, and Ipamorelin: How These Research Peptides Compare

AOD 9604, MOTS-c, tesamorelin, and ipamorelin are four different peptides that are often discussed together in fat-loss and growth-hormone research. They are not interchangeable: tesamorelin is an FDA-approved prescription drug for a specific diagnosis, while AOD 9604, MOTS-c, and ipamorelin are sold as research chemicals and are not approved for general human use in the United States.

What Each Peptide Is

AOD 9604 is a synthetic fragment of human growth hormone, corresponding to amino acids 176–191. Researchers study it for effects on fat metabolism, especially lipolysis, without the blood-sugar changes linked to full growth hormone. AOD 9604 is sometimes labeled HGH fragment 176–191, which refers to the same molecule.

MOTS-c is a mitochondrial-derived peptide encoded in the 12S rRNA gene. It is researched for roles in insulin sensitivity, metabolic homeostasis, and exercise response.

Tesamorelin is a growth-hormone-releasing hormone (GHRH) analog. The FDA approved it in 2010 under the brand name Egrifta to reduce excess visceral fat in adults with HIV-associated lipodystrophy.

Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor. It is studied for stimulating GH release with less effect on cortisol and appetite than older secretagogues.

All four are typically administered by subcutaneous injection in research settings. None are approved as oral fat-loss drugs.

Side-by-Side Comparison

Peptide	Class	Primary Research Focus	FDA Status
AOD 9604	HGH fragment (176–191)	Fat metabolism and lipolysis	Not approved for human use
MOTS-c	Mitochondrial-derived peptide	Insulin sensitivity and metabolic regulation	Not approved for human use
Tesamorelin	GHRH analog	Visceral fat reduction and GH stimulation	Approved for HIV-associated lipodystrophy
Ipamorelin	GH secretagogue	Growth hormone release and recovery research	Not approved for human use

The table above shows that only tesamorelin has an FDA-approved indication. AOD 9604, MOTS-c, and ipamorelin remain experimental for human use.

AOD 9604 vs Tesamorelin vs MOTS-c: Key Differences

When people compare aod 9604 vs tesamorelin, the main distinction is mechanism. Tesamorelin raises growth hormone through the pituitary gland, while AOD 9604 is designed to act on fat tissue without substantially raising GH or IGF-1.

Looking at aod 9604 vs mots-c, the two peptides come from very different places. AOD 9604 is a growth hormone fragment, and MOTS-c is a mitochondrial peptide tied to insulin sensitivity and cellular energy use.

Researchers also examine aod-9604 and mots-c together in metabolic studies, but the combination has not been tested in large human trials. Ipamorelin is often grouped with these peptides because it also affects growth hormone, yet it works through a separate receptor pathway.

AOD 9604 is not a growth hormone secretagogue, so it is not a direct substitute for ipamorelin or tesamorelin in GH-focused research.

What Human Studies Show

Tesamorelin has the strongest human evidence in this group. Randomized trials in adults with HIV-associated lipodystrophy show reductions in visceral adipose tissue, which led to FDA approval. Tesamorelin has also been studied in adults without HIV, but those uses are not FDA-approved.

AOD 9604 has been tested in animals and in a small number of human studies, but results have been mixed and the FDA has not approved it for weight loss or any other human use.

MOTS-c research is mostly limited to animal and cell studies. Human data on metabolic effects are sparse.

Ipamorelin has early human studies showing growth hormone release, but long-term effects on body composition and safety are not well established.

Stacking and Dosage Discussions

A frequent topic in online research communities is the aod-9604 mots-c tesamorelin stack, which combines a GH fragment, a mitochondrial peptide, and a GHRH analog. People searching for aod 9604 mots-c tesamorelin dosage are usually looking for a combined protocol, but no established human dosing schedule exists for this combination.

It is important to separate approved labeling from experimental use. Tesamorelin has a specific FDA-approved dose for its labeled indication, while AOD 9604, MOTS-c, and ipamorelin do not have FDA-approved doses for any condition.

Doses mentioned in forums or animal studies cannot be directly translated to humans. Anyone considering these compounds should discuss risks and monitoring with a healthcare professional.

Safety, Legal Status, and Practical Considerations

Tesamorelin is a prescription product, and its use requires a diagnosis, a prescription, and medical monitoring. AOD 9604, MOTS-c, and ipamorelin are not FDA-approved for human use, so products sold online are not subject to the same quality or purity standards as approved drugs.

Reported side effects from growth-hormone-related peptides can include injection-site reactions, joint pain, swelling, and changes in blood sugar. Long-term safety data for AOD 9604, MOTS-c, and ipamorelin in healthy adults are limited.

Because these peptides are often sold as research chemicals, purity and labeling can vary widely. A healthcare professional can help you understand approved options and whether any monitoring is appropriate.

In short, tesamorelin is the only peptide in this group with FDA approval, and that approval is narrow. AOD 9604, MOTS-c, and ipamorelin remain experimental for human fat loss and performance use.

RELATED PEPTIDE TOPICIpamorelin peptide

COMMON QUESTIONS

Frequently Asked Questions

Is AOD 9604 the same as tesamorelin?

No. AOD 9604 is a fragment of human growth hormone, while tesamorelin is a growth-hormone-releasing hormone analog. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, and AOD 9604 is not FDA-approved for any human use.

What is the AOD 9604 MOTS-c tesamorelin dosage?

There is no standard or approved dosage for combining AOD 9604, MOTS-c, and tesamorelin. Tesamorelin has a labeled dose for its approved indication, but AOD 9604 and MOTS-c do not have established human dosing. Any combined protocol found online is experimental and lacks large clinical trial support.

Can you stack AOD 9604, MOTS-c, tesamorelin, and ipamorelin together?

No published human trials have tested all four peptides together, so the safety and effectiveness of this stack are unknown. Combining multiple research peptides can increase the risk of side effects and interactions. A healthcare professional can discuss approved treatments and appropriate monitoring.